News Search Results
Aug 07, 2025, 08:31 ET MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the second quarter ended June
More news about: MetaVia Inc.
Aug 07, 2025, 08:00 ET K36 Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for KTX-2001 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Announces Clinical Trial Collaboration with Bayer for Supply of Darolutamide
Aug. 7, 2025 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a privately held clinical-stage biotechnology company developing novel, targeted therapies for cancers with unmet medical need, today announced the US Food and Drug Administration (FDA) has
More news about: K36 Therapeutics
Aug 07, 2025, 07:30 ET Switch Bioworks Expands Leadership Team and Moves into New Facility to Accelerate Development of its Microbial Fertilizer Products
SAN FRANCISCO, Aug. 7, 2025 /PRNewswire/ -- Switch Bioworks, a biotechnology company developing low-cost and sustainable fertilizers, announced today the addition of two senior leaders to its executive team and a move into
More news about: Switch Bioworks
Aug 07, 2025, 07:28 ET ARTBIO Appoints Four New Board Members, Co-Founder Transitions to Technical Advisory Board Role
most recently served as Head of Equity Capital Markets in the Americas. While at Goldman Sachs, Mr. Gelman advised on and led many high-profile biotechnology financings. Mr. Gelman holds a B.S.E. in Industrial Engineering from the University of Michigan."Following
More news about: ARTBIO
Aug 07, 2025, 07:05 ET REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights
Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Aug 07, 2025, 07:00 ET REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy
treatment or retinal laser; surgical treatment may be required for advanced PDR.2 ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Aug 07, 2025, 06:45 ET Lilly reports second-quarter 2025 financial results and raises guidance
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Aug 07, 2025, 06:30 ET Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today
More news about: Immunic, Inc.
Aug 07, 2025, 06:30 ET Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results
Oliger to its board of directors. Ms. Oliger brings more than 30 years of commercial and business experience in the pharmaceutical and biotechnology industry to the Nuvalent board. Most recently, Ms. Oliger served as Senior Vice President of the Oncology Business Unit at Genentech, where she
More news about: Nuvalent, Inc.
Aug 07, 2025, 06:25 ET Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Aug 07, 2025, 01:00 ET Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®
masses in India. Intas' biosimilars are manufactured at Intas Pharmaceuticals' European Union- Good Manufacturing Practices (EU-GMP) certified biotechnology plant located near Ahmedabad, Gujarat. For more information, visit
More news about: Accord Healthcare
Aug 06, 2025, 19:56 ET XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration
intelligence (AI) and robotics for drug and materials discovery, announced a transformative strategic collaboration with DoveTree Medicines, a biotechnology pioneer founded by renowned drug developer Dr. Gregory Verdine. The collaboration, worth up to $5.99
More news about: XtalPi Inc.
Aug 06, 2025, 16:30 ET Essa Pharma Inc. Announces US$80 Million Cash Distribution to Shareholders
is being held to consider and approve the Company's previously announced transaction with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding Common Shares (the "Transaction"), which meeting is expected to
More news about: ESSA Pharma Inc.
Aug 06, 2025, 16:30 ET Corteva Delivers Strong 1H 2025, Raises Full-Year Guidance
commercialize the company's pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of the company's biotechnology and other agricultural products; (iv) effect of changes in agricultural and related policies of governments and international organizations; (v)
More news about: Corteva Agriscience
Aug 06, 2025, 16:06 ET Freenome Announces Exclusive License Agreement with Exact Sciences to Commercialize Freenome's Blood-Based Screening Test for Colorectal Cancer
BRISBANE, Calif., Aug. 6, 2025 /PRNewswire/ -- Freenome, a biotechnology company pioneering an early cancer detection platform, today announced an exclusive license agreement with Exact Sciences to advance the commercialization
More news about: Freenome Holdings, Inc.
Aug 06, 2025, 12:16 ET Clara Jensen Joins Rubin and Rudman's Trusts and Estates Group
Rubin and Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin and Rudman
Aug 06, 2025, 11:12 ET Advanced In Vivo Efficacy Models for Preclinical Success, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Aug 06, 2025, 10:45 ET Biomarkers Market to Grow at a CAGR of 12.3% from 2025 to 2032 | SkyQuest Technology Consulting
treatment plans to individual genetic profiles, improving efficacy and minimizing side effects.By end user, pharmaceutical and biotechnology companies dominate since they invest heavily in biomarker development to accelerate drug discovery, clinical trials, and market approvals.Buy
More news about: SkyQuest Technology
Aug 06, 2025, 10:29 ET Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®
masses in India. Intas' biosimilars are manufactured at Intas Pharmaceuticals' European Union- Good Manufacturing Practices (EU-GMP) certified biotechnology plant located near Ahmedabad, Gujarat. For more information, visit
More news about: Intas Pharmaceuticals Ltd
Aug 06, 2025, 10:01 ET Pharmaceutical Suppositories Market is expected to generate a revenue of USD 2.74 Billion by 2032, Globally, at 5.91% CAGR: Verified Market Research®
(Genomics, Transcriptomics, Proteomics, Metabolomics), By Deployment Mode (Public Cloud, Private Cloud, Hybrid Cloud), By End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Hospitals and Clinics), By Geography, And Forecast
More news about: Verified Market Research
Aug 06, 2025, 10:01 ET New Report Forecasts $1.8B Helicopter Hoists Winches and Hooks Market by 2031, Fueled by EMS and Aerial Firefighting | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Aug 06, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG
[Click here for information about joining the class action] PepGen is a clinical-stage biotechnology company that focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases.
More news about: Pomerantz LLP
Aug 06, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against 3D Systems Corporation and Certain Officers - DDD
Medicine Program focuses on "the use of additive manufacturing for human organ transplantation." Since 2018, 3D Systems has partnered with the biotechnology company United Therapeutics Corporation ("United") "with a long-term goal of developing the capability to 3D print lungs that will allow patients
More news about: Pomerantz LLP
Aug 06, 2025, 08:31 ET MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient
Aug. 6, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has extended to 8 weeks from 4 weeks, the 48 mg, multiple ascending
More news about: MetaVia Inc.
Aug 06, 2025, 08:30 ET AI in Bioprocessing Today -- Accelerate. Predict. Deliver., Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Honeycomb Worldwide Inc.